GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Subscribe To Our Newsletter & Stay Updated